Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN).  Under the terms of the proposed transaction, shareholders of Checkmate will receive only $10.50 in cash for each share of Checkmate that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.